KCM
EBS icon

Kennedy Capital Management’s Emergent Biosolutions EBS Stock Holding History

Kennedy Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-220,683
Closed -$4.63M – 618
2022
Q3 		$4.63M Buy
+220,683
New +$6.14M 0.14% 270
2021
Q2 		– Sell
-12,661
Closed -$1.18M – 638
2021
Q1 		$1.18M Sell
12,661
-35,078
-73% -$3.59M 0.02% 542
2020
Q4 		$4.28M Buy
47,739
+30,014
+169% +$2.75M 0.1% 382
2020
Q3 		$1.83M Sell
17,725
-28,011
-61% -$3.02M 0.05% 494
2020
Q2 		$3.62M Buy
45,736
+7,792
+21% +$581K 0.1% 370
2020
Q1 		$2.19M Buy
37,944
+1,187
+3% +$68.4K 0.08% 435
2019
Q4 		$1.98M Sell
36,757
-49,766
-58% -$2.7M 0.05% 547
2019
Q3 		$4.52M Sell
86,523
-1,510
-2% -$70.3K 0.11% 351
2019
Q2 		$4.25M Sell
88,033
-2,698
-3% -$129K 0.1% 369
2019
Q1 		$4.58M Sell
90,731
-4,182
-4% -$247K 0.11% 353
2018
Q4 		$5.63M Sell
94,913
-57,682
-38% -$3.72M 0.14% 277
2018
Q3 		$10M Sell
152,595
-18,356
-11% -$1.07M 0.19% 179
2018
Q2 		$8.63M Sell
170,951
-11,703
-6% -$610K 0.16% 213
2018
Q1 		$9.62M Sell
182,654
-41,347
-18% -$2.06M 0.19% 162
2017
Q4 		$10.4M Sell
224,001
-9,541
-4% -$402K 0.19% 165
2017
Q3 		$9.45M Buy
233,542
+154,073
+194% +$5.57M 0.17% 189
2017
Q2 		$2.69M Sell
79,469
-85,144
-52% -$2.63M 0.05% 541
2017
Q1 		$4.78M Sell
164,613
-12,454
-7% -$379K 0.08% 431
2016
Q4 		$5.82M Sell
177,067
-3,944
-2% -$118K 0.1% 352
2016
Q3 		$5.71M Buy
181,011
+1,224
+0.7% +$35.6K 0.11% 329
2016
Q2 		$5.06M Buy
179,787
+85,978
+92% +$3.37M 0.1% 343
2016
Q1 		$3.41M Sell
93,809
-59,915
-39% -$2.12M 0.07% 466
2015
Q4 		$6.15M Sell
153,724
-100,847
-40% -$3.52M 0.12% 300
2015
Q3 		$7.25M Sell
254,571
-67,851
-21% -$2.24M 0.15% 247
2015
Q2 		$10.6M Sell
322,422
-11,687
-3% -$362K 0.19% 167
2015
Q1 		$9.61M Sell
334,109
-13,394
-4% -$384K 0.17% 204
2014
Q4 		$9.46M Buy
347,503
+85,347
+33% +$2.03M 0.17% 201
2014
Q3 		$5.59M Buy
+262,156
New +$6M 0.11% 340

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Kennedy Capital Management's EBS Position: Q4 2022 in Review

Kennedy Capital Management sold out of Emergent Biosolutions (EBS) in Q4 2022, closing a stake of 220,683 shares — an estimated $4.63M sold.

Kennedy Capital Management first reported a position in EBS in Q3 2014 and held it in 28 quarters. The position peaked at $10.6M in Q2 2015. 198 funds tracked by Wall St. Rank hold EBS as of Q4 2022.

  • Kennedy Capital Management reported no remaining Emergent Biosolutions position as of Q4 2022 after selling out during the quarter.
  • Kennedy Capital Management sold 220,683 Emergent Biosolutions shares in Q4 2022, an estimated $4.63M.
  • Kennedy Capital Management first reported a position in Emergent Biosolutions in Q3 2014 and held it in 28 quarters.
  • Kennedy Capital Management's Emergent Biosolutions position peaked at $10.6M in Q2 2015.
  • 198 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2022.

Based on Kennedy Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.